Literature DB >> 20823880

Finding the tumor copycat. Therapy fails, patients don't.

Lee M Ellis1, Isaiah J Fidler.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20823880     DOI: 10.1038/nm0910-974

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  12 in total

Review 1.  AACR centennial series: the biology of cancer metastasis: historical perspective.

Authors:  James E Talmadge; Isaiah J Fidler
Journal:  Cancer Res       Date:  2010-07-07       Impact factor: 12.701

2.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Authors:  Susumu Kobayashi; Titus J Boggon; Tajhal Dayaram; Pasi A Jänne; Olivier Kocher; Matthew Meyerson; Bruce E Johnson; Michael J Eck; Daniel G Tenen; Balázs Halmos
Journal:  N Engl J Med       Date:  2005-02-24       Impact factor: 91.245

Review 3.  Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis.

Authors:  Robert R Langley; Isaiah J Fidler
Journal:  Endocr Rev       Date:  2007-04-04       Impact factor: 19.871

4.  The consensus coding sequences of human breast and colorectal cancers.

Authors:  Tobias Sjöblom; Siân Jones; Laura D Wood; D Williams Parsons; Jimmy Lin; Thomas D Barber; Diana Mandelker; Rebecca J Leary; Janine Ptak; Natalie Silliman; Steve Szabo; Phillip Buckhaults; Christopher Farrell; Paul Meeh; Sanford D Markowitz; Joseph Willis; Dawn Dawson; James K V Willson; Adi F Gazdar; James Hartigan; Leo Wu; Changsheng Liu; Giovanni Parmigiani; Ben Ho Park; Kurtis E Bachman; Nickolas Papadopoulos; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu
Journal:  Science       Date:  2006-09-07       Impact factor: 47.728

Review 5.  Colorectal cancer.

Authors:  David Cunningham; Wendy Atkin; Heinz-Josef Lenz; Henry T Lynch; Bruce Minsky; Bernard Nordlinger; Naureen Starling
Journal:  Lancet       Date:  2010-03-20       Impact factor: 79.321

6.  Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.

Authors:  Leonard B Saltz; Heinz-Josef Lenz; Hedy L Kindler; Howard S Hochster; Scott Wadler; Paulo M Hoff; Nancy E Kemeny; Ellen M Hollywood; Mithat Gonen; Marcus Quinones; Meroe Morse; Helen X Chen
Journal:  J Clin Oncol       Date:  2007-09-17       Impact factor: 44.544

7.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

8.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Authors:  Charles D Blanke; Cathryn Rankin; George D Demetri; Christopher W Ryan; Margaret von Mehren; Robert S Benjamin; A Kevin Raymond; Vivien H C Bramwell; Laurence H Baker; Robert G Maki; Michael Tanaka; J Randolph Hecht; Michael C Heinrich; Christopher D M Fletcher; John J Crowley; Ernest C Borden
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

9.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

Authors:  Michael C Heinrich; Christopher L Corless; George D Demetri; Charles D Blanke; Margaret von Mehren; Heikki Joensuu; Laura S McGreevey; Chang-Jie Chen; Annick D Van den Abbeele; Brian J Druker; Beate Kiese; Burton Eisenberg; Peter J Roberts; Samuel Singer; Christopher D M Fletcher; Sandra Silberman; Sasa Dimitrijevic; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2003-12-01       Impact factor: 44.544

10.  Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.

Authors:  Jolien Tol; Miriam Koopman; Annemieke Cats; Cees J Rodenburg; Geert J M Creemers; Jolanda G Schrama; Frans L G Erdkamp; Allert H Vos; Cees J van Groeningen; Harm A M Sinnige; Dirk J Richel; Emile E Voest; Jeroen R Dijkstra; Marianne E Vink-Börger; Ninja F Antonini; Linda Mol; Johan H J M van Krieken; Otilia Dalesio; Cornelis J A Punt
Journal:  N Engl J Med       Date:  2009-02-05       Impact factor: 91.245

View more
  50 in total

1.  Role of docosahexaenoic acid in enhancement of docetaxel action in patient-derived breast cancer xenografts.

Authors:  Marnie Newell; Susan Goruk; Vera Mazurak; Lynne Postovit; Catherine J Field
Journal:  Breast Cancer Res Treat       Date:  2019-06-24       Impact factor: 4.872

2.  Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics.

Authors:  Mike Mattie; Ashley Christensen; Mi Sook Chang; William Yeh; Suzanne Said; Yuriy Shostak; Linnette Capo; Alla Verlinsky; Zili An; Ingrid Joseph; Yi Zhang; Sathish Kumar-Ganesan; Karen Morrison; David Stover; Pia Challita-Eid
Journal:  Neoplasia       Date:  2013-10       Impact factor: 5.715

Review 3.  The seed and soil hypothesis revisited--the role of tumor-stroma interactions in metastasis to different organs.

Authors:  Robert R Langley; Isaiah J Fidler
Journal:  Int J Cancer       Date:  2011-03-25       Impact factor: 7.396

4.  Development of a multicellular pancreatic tumor microenvironment system using patient-derived tumor cells.

Authors:  Daniel Gioeli; Chelsi J Snow; Michael B Simmers; Stephen A Hoang; Robert A Figler; J Ashe Allende; Devin G Roller; J Thomas Parsons; Julia D Wulfkuhle; Emanuel F Petricoin; Todd W Bauer; Brian R Wamhoff
Journal:  Lab Chip       Date:  2019-03-27       Impact factor: 6.799

5.  Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment.

Authors:  Elena Garralda; Keren Paz; Pedro P López-Casas; Siân Jones; Amanda Katz; Lisa M Kann; Fernando López-Rios; Francesca Sarno; Fátima Al-Shahrour; David Vasquez; Elizabeth Bruckheimer; Samuel V Angiuoli; Antonio Calles; Luis A Diaz; Victor E Velculescu; Alfonso Valencia; David Sidransky; Manuel Hidalgo
Journal:  Clin Cancer Res       Date:  2014-03-14       Impact factor: 12.531

Review 6.  Phenotypic screening in cancer drug discovery - past, present and future.

Authors:  John G Moffat; Joachim Rudolph; David Bailey
Journal:  Nat Rev Drug Discov       Date:  2014-07-18       Impact factor: 84.694

Review 7.  Epithelial cancers in the post-genomic era: should we reconsider our lifestyle?

Authors:  Jeff M P Holly; Li Zeng; Claire M Perks
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

8.  VE-cadherin promotes vasculogenic mimicry by modulating kaiso-dependent gene expression.

Authors:  Daniel Delgado-Bellido; Mónica Fernández-Cortés; María Isabel Rodríguez; Santiago Serrano-Sáenz; Arkaitz Carracedo; Angel Garcia-Diaz; F Javier Oliver
Journal:  Cell Death Differ       Date:  2018-05-21       Impact factor: 15.828

9.  The promise of patient-derived xenografts: the best laid plans of mice and men.

Authors:  Scott Kopetz; Robert Lemos; Garth Powis
Journal:  Clin Cancer Res       Date:  2012-08-21       Impact factor: 12.531

10.  Intraosseous inoculation of tumor cells into bone marrow promotes distant metastatic tumor development: A novel tool for mechanistic and therapeutic studies.

Authors:  Jeffry Cutrera; Blake Johnson; Lee Ellis; Shulin Li
Journal:  Cancer Lett       Date:  2012-10-27       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.